{"id":3355,"date":"2015-06-04T21:18:07","date_gmt":"2015-06-04T21:18:07","guid":{"rendered":"http:\/\/www.medicalmarijuanainc.com\/?p=2853"},"modified":"2015-06-04T21:18:07","modified_gmt":"2015-06-04T21:18:07","slug":"axim-biotech-announces-hemp-innovations-for-life-sciences","status":"publish","type":"post","link":"https:\/\/medicalmarijuanainc.com\/2015\/06\/04\/axim-biotech-announces-hemp-innovations-for-life-sciences\/","title":{"rendered":"AXIM Biotech Announces Hemp Innovations for Life Sciences"},"content":{"rendered":"

Global Industrial Hemp Bioscience Company Announces Entry Into Food and Pharmaceutical Markets<\/h3>\n

SAN DIEGO, June 4, 2015 (GLOBE NEWSWIRE) — AXIM Biotechnologies<\/a>, Inc. (OTC:AXIM) is a unique biotechnology corporation with a focus on global research, development and production of pharmaceutical, nutraceutical, food and cosmetic products \u2013 all derived or related to hemp. The Company’s core belief is responsibility for environmental stewardship combined with development of innovative products to address current conditions with no known effective treatment including: Parkinson’s disease, Alzheimer’s disease,\u00a0dementia, ADHD (attention deficit hyperactivity disorder), PTSD, autism, MS, spasticity, pain, RLS (restless leg syndrome), glaucoma, IBD, IBS and Crohn’s disease.<\/p>\n

\"Axim<\/p>\n

“We are very proud to be able to create a highly diversified corporate entity working on numerous ground-breaking bio-technological innovations,” states George E. Anastassov, MD, DDS, MBA and CEO of AXIM Biotech. We believe that there is no comparable company in the biosciences space and especially as related to cannabinoids and hemp derived products. Not only we are working on issues for which there are currently no effective solutions but we are doing it while being environmentally and fiscally conservative.”<\/p>\n

The cannabis-based pharmaceutical market is evolving. AXIM Biotech is producing a broad scope of proprietary delivery mechanisms for the introduction of natural components of the cannabis (hemp) plant known as cannabinoids (e.g. CBD, CBG, THC, etc.). AXIM Biotech’s intellectual property, to date, includes many patent applications in various stages of application, with additional inventions to be filed soon, as well as trademark applications; many of them are approved trademarks.\u00a0Any of AXIM’s products are supported by solid intellectual property prior to being produced and distributed worldwide.<\/p>\n

As the exclusive license recipient<\/a> to the world’s first controlled-release chewing gum containing cannabinoids, AXIM Biotechnologies is pursuing two global markets: food with CanChew\u00ae<\/sup> Plus and pharmaceutical with MedChew RX\u2122.\u00a0Award-winning CanChew<\/a>\u00ae<\/sup> gum, a food product, is available today; CanChew\u00ae<\/sup> Plus is planned to be available soon. MedChew RX\u2122 is undergoing clinical trials with the intent for obtaining FDA and EMA registration as a pharmaceutical compound for treatment of pain and spasticity.<\/p>\n

Another “world’s first” are AXIM Biotech’s cannabigerol (CBG) ORAXIMAX\u2122 oral care and RENECANN\u2122 cosmetics retail products timed for delivery in the 3rd<\/sup> quarter of this year. These all-natural CBG retail products from AXIM Biotech will be priced similarly to other retail products in categories including:<\/p>\n